Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Luteolin is effective in the non-small cell lung cancer model with L858R/T790M EGF receptor mutation and erlotinib resistance.

British journal of pharmacology - 1 Jun 2014

Hong Zhuan, Cao Xiang, Li Na, Zhang Yizhou, Lan Lei, Zhou Yi, Pan Xiaolong, Shen Lei, Yin Zhimin, Luo Lan

Abstract excerpt

BACKGROUND AND PURPOSE: Non-small cell lung cancer (NSCLC) is one of the most commonly diagnosed malignancies in the world. Small-molecule inhibitors of the EGF receptor's tyrosine kinase domain (TKIs), including gefitinib and erlotinib, have been widely used for treating NSCLC. Unfortunately, nearly all patients after initially experiencing a marked improvement while on these drugs, eventually progress to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Cell Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Erlotinib Hydrochloride

Share to HSP90 Heat-Shock Proteins

Share to Mice, Nude

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Open in PubMed Open full text

Identifiers

PMID: 24471765
DOI: 10.1111/bph.12610
PMCID: PMC4243859

Genes

EGF
CCK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Luteolin is effective in the non-small cell lung cancer model with L858R/T790M EGF receptor mutation and erlotinib resistance.PMID 24471765Read ↗

Lutein inhibits tumor progression through the ATR /Chk1/p53 signaling pathway in non‐small cell lung cancerSemantic proximity Read ↗

Lutein Inhibits Cell Growth and Activates Apoptosis via the PI3K/AKT/mTOR Signaling Pathway in A549 Human Non-Small-Cell Lung Cancer CellsSemantic proximity Read ↗

Parthenolide inhibits the growth of non-small cell lung cancer by targeting epidermal growth factor receptorSemantic proximity Read ↗

Identification of luteolin -7-glucoside and epicatechin gallate from Vernoniacinerea, as novel EGFR L858R kinase inhibitors against lung cancer: Docking and simulation-based study.Semantic proximity Read ↗

Oleandrin-mediated suppression of MELK induces apoptosis, autophagy, and ferroptosis in human non-small cell lung cancer cellsSemantic proximity Read ↗

Liriopesides B induces apoptosis and cell cycle arrest in human non‑small cell lung cancer cellsSemantic proximity Read ↗

Breast Cancer Apoptosis and the Therapeutic Role of LuteolinSemantic proximity Read ↗

Luteolin inhibits A549 cells proliferation and migration by down-regulating androgen receptorsSemantic proximity Read ↗

The Regulation of Endoplasmic Reticulum Stress in Cancer: Special Focuses on Luteolin PatentsSemantic proximity Read ↗

Deguelin suppresses non-small cell lung cancer by inhibiting EGFR signaling and promoting GSK3β/FBW7-mediated Mcl-1 destabilization.Semantic proximity Read ↗

Antineoplastic Effects of Erufosine on Small and Non-Small Lung Cancer Cells Through Induction of Apoptosis and Cell Cycle ArrestSemantic proximity Read ↗

The soybean-derived peptide lunasin inhibits non-small cell lung cancer cell proliferation by suppressing phosphorylation of the retinoblastoma proteinSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.